IDENTIFICATION OF ANTIMICROBIAL AGENTS AND TARGETS

抗菌剂和目标的鉴定

• 批准号: 6298446
• 负责人: SERGUEI Y GOLOVINE
• 金额: $ 10万
• 依托单位: PINNACLE PHARMACEUTICALS
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-06-01 至 2002-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6298446
• 关键词: antiinfective agents; biological products; drug discovery /isolation; high throughput technology; multidrug resistance; nucleic acid metabolism; nucleic acid sequence; plasmids

Antibiotics previously effective against pathogenic bacteria are rapidly being compromised by the spread of multiply resistant strains. Pinnacle Pharmaceuticals was formed to address this situation through the use of assays that target novel events in macromolecular metabolism, with a platform technology in RNA metabolism. Preliminary results suggest a novel proprietary technology for the rapid identification of antimicrobial agents and their targets. Phase I of this program has the goal of identifying these novel agents and targets, thereby validating the research strategy. Phase II research is directed toward the characterization and development of the agents identified in Phase I, as well as the extension of the technology to other pathogens. PROPOSED COMMERCIAL APPLICATION: Antimicrobial agents are needed to counter the rise in drug-resistant pathogens. Pinnacle Pharmaceuticals was formed to develop novel assay systems to aid in the discovery of new therapeutic agents.

以前对病原菌有效的抗生素正在迅速被 由于多重耐药菌株的传播而受到损害。品尼高制药公司 成立是为了通过使用针对新颖的检测来解决这种情况 利用 RNA 平台技术研究大分子代谢事件 代谢。初步结果表明，一种新颖的专有技术可快速 抗菌药物及其靶标的鉴定。该计划的第一阶段有 识别这些新药物和靶标的目标，从而验证研究 战略。第二阶段研究旨在表征和开发 第一阶段确定的药物的数量，以及将该技术扩展到其他领域 病原体。 拟议的商业应用： 需要抗菌药物来应对耐药病原体的增加。 Pinnacle Pharmaceuticals 的成立是为了开发新颖的分析系统，以帮助 新治疗剂的发现。